Criminal Charges Filed Against Opioid Distributor — First Case

Criminal Charges Filed Against Opioid Distributor: First Prosecution Sets Precedent for Wholesale Drug Distributors

The U.S. Department of Justice filed criminal charges against Morris & Dickson Co., LLC, a Louisiana-based wholesale drug distributor, marking the first criminal prosecution of a pharmaceutical distributor under the Controlled Substances Act. The indictment alleges the company ignored suspicious orders of oxycodone and hydrocodone between 2014 and 2018, failing to maintain effective controls against diversion as required under 21 CFR 1301.74(b). This prosecution signals a departure from the civil enforcement model that has historically governed wholesale drug distributor oversight.

Regulatory Framework for Distributor Controlled Substance Obligations

Wholesale drug distributors handling Schedule II-V controlled substances operate under dual regulatory authority: the Drug Enforcement Administration (DEA) and state boards of pharmacy. Under 21 U.S.C. § 823(b), distributors must register with DEA and design and operate a system to detect suspicious orders. The regulation at 21 CFR 1301.74(b) requires distributors to "design and operate a system to disclose to the registrant suspicious orders of controlled substances" and inform DEA of those orders.

DEA's 2007 guidance clarified that suspicious order monitoring is not limited to orders that are obviously illegal. Distributors must evaluate order size, frequency, patterns deviating from normal medical use, and other red flags. The guidance places the burden on distributors to investigate and, where warranted, refuse or report orders—not merely to establish a monitoring system on paper.

Historically, DEA enforcement against distributors took the form of civil penalties, consent decrees, and license suspensions. Between 2008 and 2021, DEA issued approximately $400 million in civil fines against distributors. Criminal prosecution was reserved for cases involving deliberate collusion with illegal pill mills or knowingly supplying non-legitimate pharmacies. Morris & Dickson represents the first time DOJ has pursued criminal charges based on failure to maintain adequate controls, rather than active participation in diversion.

Details of the Morris & Dickson Indictment

The indictment alleges that Morris & Dickson filled orders from pharmacies in Louisiana, Alabama, and Mississippi that exhibited clear indicators of diversion: pharmacies in small towns ordering volumes inconsistent with local population, cash-only operations, and pharmacies flagged by other distributors. According to the indictment, the company's compliance program failed to investigate these red flags, and in some cases, employees allegedly overrode system alerts to continue filling orders.

DOJ charged Morris & Dickson under 21 U.S.C. § 841(a)(1) (distribution of controlled substances) and 21 U.S.C. § 846 (conspiracy), statutes typically applied to trafficking organizations. The criminal penalties under these statutes include up to 20 years imprisonment per count for individuals and unlimited fines for corporations. The indictment names the company, not individual executives, though subsequent filings may add individual defendants.

DEA simultaneously issued an Immediate Suspension Order (ISO) under 21 U.S.C. § 824(a), halting Morris & Dickson's authority to distribute controlled substances. This administrative action runs parallel to the criminal case. ISOs are reserved for situations where continued registration poses an imminent danger to public health—DEA has issued fewer than 10 ISOs against distributors in the past decade.

Implications for Wholesale Drug Distributors

This prosecution expands distributor liability beyond the civil enforcement framework. Distributors with DEA registrations now face potential criminal exposure for compliance program failures, not just for knowing participation in diversion. The indictment effectively redefines what constitutes "adequate controls" under 21 CFR 1301.74(b)—a paper compliance program is insufficient if it does not result in the actual detection and refusal of suspicious orders.

Distributors handling controlled substances should expect heightened DEA scrutiny of their suspicious order monitoring systems. Specifically, DEA will evaluate whether systems produce actionable alerts, whether staff investigate those alerts, and whether the company refuses or reports orders that cannot be explained by legitimate medical need. Documentation of these decisions is now a criminal exposure issue, not merely a regulatory compliance matter.

State boards of pharmacy may also intensify oversight. Many states incorporate DEA compliance into their wholesale drug distributor licensure requirements. A DEA suspension or criminal charge can trigger state license revocation proceedings under most state pharmacy acts. Distributors operating in multiple states face cascading license actions if a single jurisdiction takes enforcement action.

What ColdChainCheck Data Shows

ColdChainCheck does not currently track DEA registration status or controlled substance handling authorization in its compliance scoring model. DEA registration data is maintained separately from the state pharmacy board licensure and FDA registration data sources that comprise the current scoring framework. Of the 1,275 wholesale drug distributors in the directory, an estimated 400-500 hold DEA registrations authorizing controlled substance distribution, based on the subset of entities whose state licenses explicitly note Schedule II-V authorization.

The Morris & Dickson prosecution highlights a gap in publicly accessible compliance signals for distributors handling controlled substances. While state pharmacy boards publish wholesale drug distributor licenses, most states do not distinguish between general-line distributors and those authorized for controlled substances. DEA's registration database is available through the agency's Registrant Bulk Data System (RBDS), but access requires an approved Registration Data Access (RDA) application. ColdChainCheck has submitted an RDA application and anticipates incorporating DEA registration status into the compliance scoring model once access is granted.

For wholesale drug distributors currently scored in the "Fair" tier (average score: 51/100, representing 919 entities), the addition of DEA registration verification would provide a clearer compliance signal for entities handling controlled substances. The current scoring model awards points for state licensure, FDA registration, and NABP accreditation, but does not capture DEA-specific compliance posture. A distributor with active state licenses and FDA registration may still face significant enforcement risk if its DEA compliance program is deficient.

Practical Steps for Compliance Officers

• Verify DEA registration independently: Check whether trading partners hold current DEA registrations at https://apps.deadiversion.usdoj.gov/webforms2/spring/main. A distributor claiming controlled substance handling capability without DEA registration is operating illegally.

• Request suspicious order monitoring documentation: Ask distributors to provide evidence of an active suspicious order monitoring system, including system design documentation, alert thresholds, investigation protocols, and records of refused orders. Generic attestations of compliance are insufficient post-Morris & Dickson.

• Cross-reference ColdChainCheck scores with DEA status: Use the ColdChainCheck directory to verify baseline compliance signals (state licenses, FDA registration, enforcement history) before requesting DEA-specific documentation. Entities with "Poor" or "Minimal" scores (47 entities total) warrant heightened scrutiny if they claim controlled substance distribution capability.

• Monitor for DEA enforcement actions: DEA publishes Immediate Suspension Orders and administrative actions in the Federal Register. ColdChainCheck tracks FDA warning letters and recalls but does not yet include DEA enforcement actions. Compliance teams should monitor https://www.deadiversion.usdoj.gov/21cfr_reports/ directly.

For additional guidance on distributor qualification workflows, see the ColdChainCheck compliance guides.

Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. Compliance obligations vary by jurisdiction and operational scope. Consult qualified legal counsel and regulatory advisors for entity-specific guidance.